Forte Biosciences (FBRX) Expected to Announce Earnings on Wednesday

Key Points

• Forte Biosciences is scheduled to release its Q2 2025 earnings results on August 13th, with analysts expecting a loss of ($1.21) per share.
• The company's latest earnings report showed a loss of ($1.37) per share, which was significantly below the consensus estimate of ($0.89).
• Analysts' opinions are mixed, with Chardan Capital maintaining a "buy" rating and a price target of $61, while Wall Street Zen downgraded their rating from "hold" to "sell."

Forte Biosciences (NASDAQ:FBRX - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($1.21) per share for the quarter.

Forte Biosciences (NASDAQ:FBRX - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($1.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.48). On average, analysts expect Forte Biosciences to post $-12 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Forte Biosciences Trading Down 2.6%

FBRX traded down $0.28 on Thursday, hitting $10.30. 127,858 shares of the company's stock traded hands, compared to its average volume of 61,826. The firm has a market cap of $67.77 million, a price-to-earnings ratio of -0.63 and a beta of 2.91. Forte Biosciences has a one year low of $4.11 and a one year high of $28.68. The company's 50 day simple moving average is $11.36 and its 200-day simple moving average is $9.61.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on FBRX. Chardan Capital reissued a "buy" rating and set a $61.00 price target on shares of Forte Biosciences in a research note on Tuesday, June 24th. Wall Street Zen lowered shares of Forte Biosciences from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.

Forte Biosciences Company Profile

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.